CAR-T cell therapy has shown remarkable efficacy in treating certain hematologic malignancies. However, it faces significant limitations, including severe cytokine release syndrome, neurotoxicity, limited efficacy against solid tumors, and high production costs. In this study, we developed a novel CAR-NK cell specifically engineered to bind therapeutic antibodies, aiming to overcome these challenges. This antibody-dependent CAR-NK system enhances tumor targeting, improves safety, and offers a more versatile and cost-effective alternative to conventional CAR-T therapies.